Welcome to DukeHealth.org.
Skip over navigation
Skip over navigation
- Home
- Patient and Visitor Info
- Physicians
- Services
- Clinical Trials
- Event Calendar
- Locations
- Health Library
- About Duke Medicine
Quick Links
Home
>
Clinical Trials
>
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adults.
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adults.
Share
The purpose of this study is to determine if a new formulation of ramelteon (TAK-375SL) is effective in decreasing the symptoms of depression associated with bipolar I disorder so the study evaluates using an additional drug to your current medication to control depression in bipolar individuals. 18-75 years old and your participation will last approximately 11 months and will include about 14 study visits to the study center. Compensation will be upto $455.00.
For more information, contact Nabila Lateef at 919-684-9701.
(REF# Pro00034212)
